ArticleTranslational andrology and urology2026
DARS2 serves as an independent prognostic factor and participates in multiple biological processes in bladder urothelial carcinoma.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder urothelial carcinoma (BLCA) is a prevalent malignant tumor within the urinary system. Aspartyl-tRNA Synthetase 2, Mitochondrial (DARS2), a key enzyme involved in mitochondrial protein synthesis, is frequently overexpressed in various cancers and is associated with clinical stage. This study aims to explore the potential of DARS2 as a prognostic biomarker and therapeutic target in BLCA, with the ultimate goal of constructing a prognostic model. Methods: Expression profiles of BLCA were obtained from The Cancer Genome Atlas (TCGA) database and the Genotype-Tissue Expression (GTEx) database, encompassing a total of 431 samples. Differential gene expression between tumor and normal tissues was first analyzed using the "limma" R package. To identify independent prognostic genes, we integrated various statistical and machine learning approaches, including univariate and multivariate Cox proportional hazards analyses, with variable selection performed via Cox proportional hazards regression with least absolute shrinkage and selection operator (LASSO). For the key gene DARS2, its expression differences were further analyzed using the edgeR method, followed by gene set enrichment analysis (GSEA) to explore associated functional pathways. Furthermore, immune cell infiltration was evaluated using multiple algorithms. The role of DARS2 in BLCA progression was systematically investigated by integrating analyses of gene mutations, tumor mutational burden (TMB), and survival outcomes. Finally, a prognostic model was constructed based on DARS2 expression levels and validated using the GSE13507 dataset from the Gene Expression Omnibus (GEO) database. Results: Based on the analytical methods described above, we observed that the expression of DARS2 messenger ribonucleic acid (mRNA) was significantly upregulated in BLCA tissues, and its elevated expression was independently associated with adverse patient prognosis. Immune infiltration analysis revealed that DARS2 expression exhibited a significant negative correlation with major immunologically active cells, such as CD4 Conclusions: Comprehensive analysis suggests that DARS2 holds promise as a potential independent prognostic biomarker for patient stratification in BLCA and may serve as a viable target for the development of immunotherapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.